首页 > 最新文献

Journal of Stem Cells最新文献

英文 中文
Antiaging Effects of an Intensive Mind and Body Therapeutic Program through Enhancement of Telomerase Activity and Adult Stem Cell Counts. 通过增强端粒酶活性和成体干细胞计数的强化身心治疗计划的抗衰老作用。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2015-01-01
Krishna S Rao, Swarup K Chakraharti, Vaishali S Dongare, K Chetana, Christina M Ramirez, Prasad S Koka, Kaushik D Deb

Objective: Key modalities of integrative medicine known to rejuvenate the mind and body are meditation, yoga, and controlled diet. It has been shown previously that intensive or prolonged mind and body therapies (MBT) may have beneficial effects on the well-being of healthy people and in patients. Telomerase activity and levels of peripheral blood adult pluripotent stem cells (PB-APSC) are reliable markers of long-term well-being that are known to decrease with age. The objective of this study is to understand the effect of our MBT program on telomerase activity and stem cells in blood collected from the participants.

Design: Here, we have investigated the effects of an intensive three weeks MBT retreat on telomerase activity and the peripheral blood stem cells in participants before and after the MBT. A total of 108 people were enrolled in the study; 38 men and 70 women (aged 18-90) randomly assigned for the study.

Results: Telomerase activity was greater in retreat participants at the end of the MBT retreat. About 45% of people showed more than one-fold increase of telomerase activity after our MBT program. Furthermore, about 27% of people showed more pronounced fold increase (2-fold) in telomerase activity after the MBT. In addition, a substantial percentage of people (about 90%) exhibited increased stem cell counts after the MBT.

Conclusions: The data suggest increased telomerase activity and stem cells count in peripheral blood from MBT retreat participants that may lead to increased longevity and better quality of life at latter age.

目的:已知的使身心恢复活力的综合医学的关键模式是冥想,瑜伽和控制饮食。以前已经表明,密集或长期的身心疗法(MBT)可能对健康人和患者的福祉产生有益影响。端粒酶活性和外周血成体多能干细胞(PB-APSC)水平是长期健康的可靠标志,随着年龄的增长而下降。本研究的目的是了解我们的MBT计划对从参与者收集的血液中端粒酶活性和干细胞的影响。设计:在这里,我们研究了密集的三周MBT退却对MBT前后参与者端粒酶活性和外周血干细胞的影响。共有108人参加了这项研究;38名男性和70名女性(年龄在18-90岁之间)被随机分配到研究中。结果:端粒酶活性在MBT撤退结束时更大的参与者。大约45%的人在我们的MBT项目后端粒酶活性增加了一倍以上。此外,约27%的人在MBT后端粒酶活性明显增加(2倍)。此外,相当大比例的人(约90%)在MBT后表现出增加的干细胞计数。结论:数据表明,MBT撤退参与者外周血端粒酶活性和干细胞计数的增加可能导致晚年寿命延长和生活质量提高。
{"title":"Antiaging Effects of an Intensive Mind and Body Therapeutic Program through Enhancement of Telomerase Activity and Adult Stem Cell Counts.","authors":"Krishna S Rao,&nbsp;Swarup K Chakraharti,&nbsp;Vaishali S Dongare,&nbsp;K Chetana,&nbsp;Christina M Ramirez,&nbsp;Prasad S Koka,&nbsp;Kaushik D Deb","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Key modalities of integrative medicine known to rejuvenate the mind and body are meditation, yoga, and controlled diet. It has been shown previously that intensive or prolonged mind and body therapies (MBT) may have beneficial effects on the well-being of healthy people and in patients. Telomerase activity and levels of peripheral blood adult pluripotent stem cells (PB-APSC) are reliable markers of long-term well-being that are known to decrease with age. The objective of this study is to understand the effect of our MBT program on telomerase activity and stem cells in blood collected from the participants.</p><p><strong>Design: </strong>Here, we have investigated the effects of an intensive three weeks MBT retreat on telomerase activity and the peripheral blood stem cells in participants before and after the MBT. A total of 108 people were enrolled in the study; 38 men and 70 women (aged 18-90) randomly assigned for the study.</p><p><strong>Results: </strong>Telomerase activity was greater in retreat participants at the end of the MBT retreat. About 45% of people showed more than one-fold increase of telomerase activity after our MBT program. Furthermore, about 27% of people showed more pronounced fold increase (2-fold) in telomerase activity after the MBT. In addition, a substantial percentage of people (about 90%) exhibited increased stem cell counts after the MBT.</p><p><strong>Conclusions: </strong>The data suggest increased telomerase activity and stem cells count in peripheral blood from MBT retreat participants that may lead to increased longevity and better quality of life at latter age.</p>","PeriodicalId":53626,"journal":{"name":"Journal of Stem Cells","volume":"10 2","pages":"107-25"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34438641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differentiation Potential of Mesenchymal Stem Cells from Equine Bone Marrow Cultured on Hyaluronic Acid-Chitosan Polyelectrolyte Multilayer Biofilm. 透明质酸-壳聚糖聚电解质多层生物膜培养马骨髓间充质干细胞的分化潜力。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2015-01-01
Amanda J Listoni, Isadora Arruda, Leandro Maia, Danielle J Barberini, Ian Martins, Fernando C Vasconcellos, Fernanda C Landim-Alvarenga

Nanotechnology techniques have a prominent role in the current technical and scientific scene. The layer-by-layer (LbL) deposition allows obtaining nanostructures with sophisticated multilayer, using a simple, but versatile technique. This procedure, which is used to coat and functionalize surfaces with nanometer- thick films, has applications in bioengineering, medicine, chemistry, materials and chemical engineering among other areas. Chitosan is a biomaterial, coming from the chitin, a very abundant polymer in nature, which has been recently tested as scaffolds. In this experiment we test the hypothesis that the hyaluronic acid-chitosan polyelectrolyte multilayer biofilm would be a good substrate to the adherence of equine mesenchymal stem cells derived from bone marrow. The results showed that these biofilms accelerate the process of cell adhesion on smooth surfaces, allowing a constant cell growth and creating a great option to cover surgical materials.

纳米技术在当前的技术和科学领域具有突出的作用。利用一种简单而通用的技术,逐层沉积可以获得复杂的多层纳米结构。该方法用于在表面涂覆纳米厚薄膜并使其功能化,在生物工程、医学、化学、材料和化学工程等领域都有应用。壳聚糖是一种生物材料,来自于自然界中含量非常丰富的聚合物几丁质,最近已被用作支架进行了测试。本实验验证了透明质酸-壳聚糖聚电解质多层生物膜作为马骨髓间充质干细胞粘附的良好底物的假设。结果表明,这些生物膜加速了细胞在光滑表面上的粘附过程,允许细胞持续生长,并为覆盖手术材料创造了一个很好的选择。
{"title":"Differentiation Potential of Mesenchymal Stem Cells from Equine Bone Marrow Cultured on Hyaluronic Acid-Chitosan Polyelectrolyte Multilayer Biofilm.","authors":"Amanda J Listoni,&nbsp;Isadora Arruda,&nbsp;Leandro Maia,&nbsp;Danielle J Barberini,&nbsp;Ian Martins,&nbsp;Fernando C Vasconcellos,&nbsp;Fernanda C Landim-Alvarenga","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Nanotechnology techniques have a prominent role in the current technical and scientific scene. The layer-by-layer (LbL) deposition allows obtaining nanostructures with sophisticated multilayer, using a simple, but versatile technique. This procedure, which is used to coat and functionalize surfaces with nanometer- thick films, has applications in bioengineering, medicine, chemistry, materials and chemical engineering among other areas. Chitosan is a biomaterial, coming from the chitin, a very abundant polymer in nature, which has been recently tested as scaffolds. In this experiment we test the hypothesis that the hyaluronic acid-chitosan polyelectrolyte multilayer biofilm would be a good substrate to the adherence of equine mesenchymal stem cells derived from bone marrow. The results showed that these biofilms accelerate the process of cell adhesion on smooth surfaces, allowing a constant cell growth and creating a great option to cover surgical materials.</p>","PeriodicalId":53626,"journal":{"name":"Journal of Stem Cells","volume":"10 2","pages":"69-77"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34438637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Duchenne Muscular Dystrophy: Safety and Feasibility Study in India. 人脐带间充质干细胞治疗杜氏肌营养不良:印度的安全性和可行性研究。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2015-01-01
B S Rajput, Swarup K Chakrabarti, Vaishali S Dongare, Christina M Ramirez, Kaushik D Deb

Objective: Duchenne muscular dystrophy (DMD) is a musculo-degenerative disease characterized by lack of dystrophin production with no definite cure available currently. Discarded umbilical cord is a potential source of mesenchymal stem cells which are non-immunogenic and can be used for transplantation in allogenic set ups. Given the regenerative and anti-inflammatory properties of mesenchymal stem cells (MSCs), here we investigated its role in the cellular therapy of DMD patients.

Design: This is a single-blinded study conducted in various hospitals of India situated in Mumbai, Delhi, and Lucknow. Inclusion criteria for enrolling the patients in the study were boys aged between 5 to 18 years, absence of dystrophin in the immunohistochemistry of muscle biopsy and mutation in dystrophin gene in cytogenetic analysis. The exclusion criteria were presence of dystrophin in the muscle biopsy, patients on corticosteroids etc. UC-MSCs (2 millions/kg body weight) were administered through IV and IM injection. Muscle power in muscles of proximal upper limb, distal upper limb, proximal lower limb, distal lower limb, hip flexors, hip extensors, hip abductors, and paraspinal muscles were measured in 11 DMD patients after UC-MSCs transplantation and were followed for up to 3 years (average follow up 1.5 years). 5 DMD patients did not receive any UC-MSCs transplantation and served as the control group.

Results: The treatment group (N = 11 at baseline) had a pretransplantation strength of 3.45 ± 1.0357 and 4.090 ± 0.8312 in muscles of proximal upper limb and distal upper limb respectively. After 1 year (N = 9) these strengths remained stable with an average of 3.78 (1.03) and 4.22 (0.83). In contrast, the control group (N = 5) has a pre-transplantation strength of 3.6 (0.54) and 4 (1) in the proximal and distal upper limb respectively. After 1 year, (N = 5) 3/5 subjects had a slight but not statistically significant decrease in the proximal upper limb, mean 3.0 (1.0) and 5/5 had a lunit decrease in strength, mean 3.0 (1.0). The treatment group had a pre-transplantation strength of 2.0909 ± 0.8312 and 3.1181 ± 0.8738 in muscles of distal and proximal lower limbs respectively. At 1 year (N = 9), 4/9 subjects had a 1 unit increase in strength in the distal lower limb (mean 3.78 (0.97)) and 8/9 subjects had a lunit increase in strength in the proximal lower limb, mean 3.11 (1.05). The control group has a mean of 3.41 (0.54) and 3.0 (1.0) at baseline in the distal and proximal lower limb respectively. By 1 year, 3/5 subjects had a 1 unit decrease (mean 2.8 (0.45)) and 5/5 had a lunit decrease, mean 2.0 (1.0) in distal and proximal lower limb strength. Stability in muscle function was also achieved in muscles of hip flexors, hip extensors, hip abductors, and paraspinal muscles at one year as compared to untreated group.

Conclusion: UC-MSCs administration not only resulted in the s

目的:杜氏肌营养不良症(DMD)是一种以肌营养不良蛋白缺乏为特征的肌肉退行性疾病,目前尚无明确的治疗方法。废弃脐带是非免疫原性间充质干细胞的潜在来源,可用于同种异体移植。鉴于间充质干细胞(MSCs)的再生和抗炎特性,我们在这里研究了它在DMD患者细胞治疗中的作用。设计:这是一项在印度孟买、德里和勒克瑙的多家医院进行的单盲研究。纳入研究患者的标准是年龄在5 - 18岁之间的男孩,肌肉活检的免疫组化检查中没有肌营养不良蛋白,细胞遗传学分析中有肌营养不良蛋白基因突变。排除标准为肌肉活检中存在肌营养不良蛋白,患者使用皮质类固醇等。UC-MSCs(200万个/kg体重)通过静脉注射和IM注射给药。对11例UC-MSCs移植后的DMD患者的上肢近端、上肢远端、下肢近端、下肢远端、髋关节屈肌、髋关节伸肌、髋关节外展肌和棘旁肌的肌力进行了测量,随访时间长达3年(平均随访时间为1.5年)。5例DMD患者未接受UC-MSCs移植,作为对照组。结果:治疗组(基线时N = 11)上肢近端和远端肌肉移植前强度分别为3.45±1.0357和4.090±0.8312。1年后(N = 9),这些优势保持稳定,平均为3.78(1.03)和4.22(0.83)。对照组(N = 5)的上肢近端和远端移植前强度分别为3.6(0.54)和4(1)。1年后,(N = 5) 3/5的受试者上肢近端有轻微但无统计学意义的下降,平均3.0(1.0),5/5的受试者力量下降,平均3.0(1.0)。治疗组移植前下肢远端和近端肌肉强度分别为2.0909±0.8312和3.1181±0.8738。1年后(N = 9), 4/9的受试者下肢远端力量增加了1个单位(平均3.78(0.97)),8/9的受试者下肢近端力量增加了1个单位,平均3.11(1.05)。对照组下肢远端和近端基线平均值分别为3.41(0.54)和3.0(1.0)。1年后,3/5的受试者下肢远端和近端强度下降1个单位(平均2.8(0.45)),5/5的受试者下肢远端和近端强度下降1个单位,平均2.0(1.0)。与未治疗组相比,髋关节屈肌、髋关节伸肌、髋关节外展肌和棘旁肌的肌肉功能在一年内也实现了稳定。结论:UC-MSCs给药不仅导致肌肉力量的稳定,而且没有显示出GVHD或对患者的任何有害影响,因此与对照组相比,可能被认为是治疗DMD的安全选择,尽管需要进一步的更大规模的双盲研究。
{"title":"Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Duchenne Muscular Dystrophy: Safety and Feasibility Study in India.","authors":"B S Rajput,&nbsp;Swarup K Chakrabarti,&nbsp;Vaishali S Dongare,&nbsp;Christina M Ramirez,&nbsp;Kaushik D Deb","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Duchenne muscular dystrophy (DMD) is a musculo-degenerative disease characterized by lack of dystrophin production with no definite cure available currently. Discarded umbilical cord is a potential source of mesenchymal stem cells which are non-immunogenic and can be used for transplantation in allogenic set ups. Given the regenerative and anti-inflammatory properties of mesenchymal stem cells (MSCs), here we investigated its role in the cellular therapy of DMD patients.</p><p><strong>Design: </strong>This is a single-blinded study conducted in various hospitals of India situated in Mumbai, Delhi, and Lucknow. Inclusion criteria for enrolling the patients in the study were boys aged between 5 to 18 years, absence of dystrophin in the immunohistochemistry of muscle biopsy and mutation in dystrophin gene in cytogenetic analysis. The exclusion criteria were presence of dystrophin in the muscle biopsy, patients on corticosteroids etc. UC-MSCs (2 millions/kg body weight) were administered through IV and IM injection. Muscle power in muscles of proximal upper limb, distal upper limb, proximal lower limb, distal lower limb, hip flexors, hip extensors, hip abductors, and paraspinal muscles were measured in 11 DMD patients after UC-MSCs transplantation and were followed for up to 3 years (average follow up 1.5 years). 5 DMD patients did not receive any UC-MSCs transplantation and served as the control group.</p><p><strong>Results: </strong>The treatment group (N = 11 at baseline) had a pretransplantation strength of 3.45 ± 1.0357 and 4.090 ± 0.8312 in muscles of proximal upper limb and distal upper limb respectively. After 1 year (N = 9) these strengths remained stable with an average of 3.78 (1.03) and 4.22 (0.83). In contrast, the control group (N = 5) has a pre-transplantation strength of 3.6 (0.54) and 4 (1) in the proximal and distal upper limb respectively. After 1 year, (N = 5) 3/5 subjects had a slight but not statistically significant decrease in the proximal upper limb, mean 3.0 (1.0) and 5/5 had a lunit decrease in strength, mean 3.0 (1.0). The treatment group had a pre-transplantation strength of 2.0909 ± 0.8312 and 3.1181 ± 0.8738 in muscles of distal and proximal lower limbs respectively. At 1 year (N = 9), 4/9 subjects had a 1 unit increase in strength in the distal lower limb (mean 3.78 (0.97)) and 8/9 subjects had a lunit increase in strength in the proximal lower limb, mean 3.11 (1.05). The control group has a mean of 3.41 (0.54) and 3.0 (1.0) at baseline in the distal and proximal lower limb respectively. By 1 year, 3/5 subjects had a 1 unit decrease (mean 2.8 (0.45)) and 5/5 had a lunit decrease, mean 2.0 (1.0) in distal and proximal lower limb strength. Stability in muscle function was also achieved in muscles of hip flexors, hip extensors, hip abductors, and paraspinal muscles at one year as compared to untreated group.</p><p><strong>Conclusion: </strong>UC-MSCs administration not only resulted in the s","PeriodicalId":53626,"journal":{"name":"Journal of Stem Cells","volume":"10 2","pages":"141-56"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34439704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer Stem Cells and Chemoresistance in Glioblastoma Multiform: A Review Article. 多形性胶质母细胞瘤的肿瘤干细胞和化疗耐药研究综述。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2015-01-01 DOI: jsc.2015.10.4.271
Mojdeh Safari, Alireza Khoshnevisan

Glioblastomamultiforme (GBM) is the most common malignant and aggressive primary tumor of the brain in adults and characterized by a heterogeneous population of cells that are genetically unstable, highly infiltrative, angiogenic, and resistant to chemotherapy. Considerable efforts being devoted to identifying the molecular basis of resistance in GBM and exploring novel therapeutic targets that may improve overall survival. Several independent DNA repair mechanisms that normally safeguard genome integrity can facilitate drug resistance and cancer cell survival by removing chemotherapy- induced adducts. The recent data suggest that the most important mechanism of resistance to alkylating agents is the DNA repair enzyme O6-methylguanine methyltransferase (MGMT). Although, the treatment failure is a result of a number of causes, but currently, it has been demonstrated that a highly tumorigenic subpopulation of cancer cells called glioblastoma stem cells (GSCs) display relative resistance to radiation and chemotherapy. In fact, GBM stem cells express high levels of MGMT and this may account for GBM resistance following chemotherapy. GSCs also contribute to tumor growth through the stimulation of angiogenesis, which has been shown to be a useful therapeutic target in the treatment of recurrent or progressive malignant gliomas. In this review, we summarize the chemoresistance mechanisms of GBMs (to alkylating agents), with a special focus on the role of cancer stem cells.

多形性胶质母细胞瘤(GBM)是成人中最常见的恶性和侵袭性原发性脑肿瘤,其特点是细胞群异质性,遗传不稳定,高度浸润,血管生成,耐化疗。在确定GBM耐药的分子基础和探索可能提高总生存率的新治疗靶点方面,人们付出了相当大的努力。一些独立的DNA修复机制通常保护基因组完整性,可通过去除化疗诱导的加合物促进耐药和癌细胞存活。最近的数据表明,对烷基化剂的抗性最重要的机制是DNA修复酶o6 -甲基鸟嘌呤甲基转移酶(MGMT)。虽然治疗失败是由多种原因造成的,但目前已经证明,一种称为胶质母细胞瘤干细胞(GSCs)的高度致瘤性癌细胞亚群对放疗和化疗表现出相对的抗性。事实上,GBM干细胞表达高水平的MGMT,这可能是化疗后GBM耐药的原因。GSCs还通过刺激血管生成促进肿瘤生长,这已被证明是治疗复发或进展性恶性胶质瘤的有用治疗靶点。在这篇综述中,我们总结了GBMs(对烷基化剂)的化学耐药机制,特别关注癌症干细胞的作用。
{"title":"Cancer Stem Cells and Chemoresistance in Glioblastoma Multiform: A Review Article.","authors":"Mojdeh Safari,&nbsp;Alireza Khoshnevisan","doi":"jsc.2015.10.4.271","DOIUrl":"https://doi.org/jsc.2015.10.4.271","url":null,"abstract":"<p><p>Glioblastomamultiforme (GBM) is the most common malignant and aggressive primary tumor of the brain in adults and characterized by a heterogeneous population of cells that are genetically unstable, highly infiltrative, angiogenic, and resistant to chemotherapy. Considerable efforts being devoted to identifying the molecular basis of resistance in GBM and exploring novel therapeutic targets that may improve overall survival. Several independent DNA repair mechanisms that normally safeguard genome integrity can facilitate drug resistance and cancer cell survival by removing chemotherapy- induced adducts. The recent data suggest that the most important mechanism of resistance to alkylating agents is the DNA repair enzyme O6-methylguanine methyltransferase (MGMT). Although, the treatment failure is a result of a number of causes, but currently, it has been demonstrated that a highly tumorigenic subpopulation of cancer cells called glioblastoma stem cells (GSCs) display relative resistance to radiation and chemotherapy. In fact, GBM stem cells express high levels of MGMT and this may account for GBM resistance following chemotherapy. GSCs also contribute to tumor growth through the stimulation of angiogenesis, which has been shown to be a useful therapeutic target in the treatment of recurrent or progressive malignant gliomas. In this review, we summarize the chemoresistance mechanisms of GBMs (to alkylating agents), with a special focus on the role of cancer stem cells.</p>","PeriodicalId":53626,"journal":{"name":"Journal of Stem Cells","volume":"10 4","pages":"271-85"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34454923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hematopoietic stem cells: potential new applications for translational medicine. 造血干细胞:转化医学的潜在新应用。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2014-01-01 DOI: jsc.2014.9.3.163
Hady Felfly, Gabriel G Haddad

Hematopoietic stem cells (HSC) are multipotent cells that produce the various lineages of blood and HSC transplantations (HSCT) are widely used to reconstitute damaged bone marrow (BM). Over time, HSCT has evolved for the treatment of non-blood diseases as well, brain in particular. However, HSCT required total myeloablation through irradiation and/or chemotherapy for the treatment of BM-related diseases, and HSCs are difficult to safely deliver in large amounts into the brain. In blood disorders, for a minimal myelosuppression to be sufficient and allow donor cells to engraft, it is necessary to determine the minimal percentage of normal BM cells needed to achieve phenotypic correction. Recent studies on animal models of ?-thalassemia and sickle cell disease (SCD), through Competitive Repopulation Assay (CRA) following lethal irradiation of recipients, demonstrated that an average of 25% normal BM cells allows the production of enough normal red blood cells to significantly correct the ?-thalassemia and SCD phenotypes, at the levels of BM, blood, histology, and survival, with normal donor cells contributing to 50-60% of peripheral red blood cells. Further assays using mild myelosuppression showed that long term sustained phenotypic correction can be obtained for both diseases through a novel transplantation strategy based on modulating four parameters: dose of irradiation/myelosuppression, number of transplanted cells, timing of cell injections, and number of cell doses. Through a minimal dose of irradiation of 1Gy (100 Rads) or 2Gy, two injections of BM cells within the first 24h after myelosuppression resulted in engraftment in 100% of mice and a sustained therapeutic mixed chimerism in ?-thalassemia, while three to four injections were needed to achieve a similar outcome in SCD. Following the success of these trials, we modified this novel HSCT strategy and applied it to determine whether we can protect mice from lethal stroke induced through the Middle Cerebral Artery Occlusion (MCAO). Ischemia/reperfusion resulted in a major infarct that propagated over time to encompass ~70% of the affected hemisphere. When two doses of HSCs were injected at 2h and 24h after the reperfusion, 40% of mice survived, visible neurological defects disappeared, and the infarct size was reduced by two to four fold. Histological examination of brains in surviving mice revealed very few donor cells in the recipient brains, decreased total neurons count and increased glial cell numbers. These data suggest that the neuro-protection was not dependent on cell-supplementation, but rather the protection is manifested likely through growth factor secretion. Combined, these studies create a novel HSCT approach that has proved efficient for the treatment of various disorders. A "window of opportunity" exists for each disease where the donor cells should be administered, and multiple injections of donor HSCs can rescue diseases that would otherwise not be treatable. We

造血干细胞(Hematopoietic stem cells, HSC)是一种多能细胞,可以产生多种血液,而造血干细胞移植(HSCT)被广泛用于重建受损的骨髓(BM)。随着时间的推移,造血干细胞移植已经发展到治疗非血液疾病,特别是脑部疾病。然而,为了治疗脑转移相关疾病,造血干细胞移植需要通过放疗和/或化疗进行全髓切除,而且造血干细胞很难安全地大量进入大脑。在血液疾病中,为了使最小的骨髓抑制足够并允许供体细胞移植,有必要确定实现表型校正所需的正常骨髓细胞的最小百分比。最近对地中海贫血和镰状细胞病(SCD)动物模型的研究,通过对受者进行致死照射后的竞争再种群测定(CRA),表明平均25%的正常骨髓细胞可以产生足够的正常红细胞,在骨髓、血液、组织学和存活水平上显著纠正地中海贫血和SCD表型,正常供体细胞贡献50-60%的外周血细胞。使用轻度骨髓抑制的进一步分析表明,通过一种基于调节四个参数的新移植策略,可以获得两种疾病的长期持续表型纠正:照射/骨髓抑制剂量、移植细胞数量、细胞注射时间和细胞剂量。通过1Gy (100 Rads)或2Gy的最小剂量照射,骨髓抑制后的头24小时内两次注射BM细胞可导致100%的小鼠移植,并在-地中海贫血中持续治疗性混合嵌合,而在SCD中需要三到四次注射才能达到类似的结果。在这些试验成功之后,我们修改了这种新的HSCT策略,并将其应用于确定我们是否可以保护小鼠免受大脑中动脉闭塞(MCAO)引起的致命中风。缺血/再灌注导致大面积梗死,随着时间的推移,梗死范围已覆盖约70%的受累半球。再灌注后2h和24h分别注射两剂造血干细胞,40%小鼠存活,可见神经缺损消失,梗死面积缩小2 ~ 4倍。对存活小鼠大脑的组织学检查显示,受体大脑中供体细胞很少,神经元总数减少,神经胶质细胞数量增加。这些数据表明,神经保护不依赖于细胞补充,而可能通过生长因子的分泌来表现。综合起来,这些研究创造了一种新的HSCT方法,已被证明对治疗各种疾病有效。每一种疾病都有一个“机会之窗”,供体造血干细胞的多次注射可以挽救原本无法治愈的疾病。我们假设,最初的注射使受影响的组织启动,随后的注射有助于修复。这一新策略为造血干细胞移植的新时代开辟了道路,为许多疾病的潜在治疗和可能治愈开辟了道路。
{"title":"Hematopoietic stem cells: potential new applications for translational medicine.","authors":"Hady Felfly,&nbsp;Gabriel G Haddad","doi":"jsc.2014.9.3.163","DOIUrl":"https://doi.org/jsc.2014.9.3.163","url":null,"abstract":"<p><p>Hematopoietic stem cells (HSC) are multipotent cells that produce the various lineages of blood and HSC transplantations (HSCT) are widely used to reconstitute damaged bone marrow (BM). Over time, HSCT has evolved for the treatment of non-blood diseases as well, brain in particular. However, HSCT required total myeloablation through irradiation and/or chemotherapy for the treatment of BM-related diseases, and HSCs are difficult to safely deliver in large amounts into the brain. In blood disorders, for a minimal myelosuppression to be sufficient and allow donor cells to engraft, it is necessary to determine the minimal percentage of normal BM cells needed to achieve phenotypic correction. Recent studies on animal models of ?-thalassemia and sickle cell disease (SCD), through Competitive Repopulation Assay (CRA) following lethal irradiation of recipients, demonstrated that an average of 25% normal BM cells allows the production of enough normal red blood cells to significantly correct the ?-thalassemia and SCD phenotypes, at the levels of BM, blood, histology, and survival, with normal donor cells contributing to 50-60% of peripheral red blood cells. Further assays using mild myelosuppression showed that long term sustained phenotypic correction can be obtained for both diseases through a novel transplantation strategy based on modulating four parameters: dose of irradiation/myelosuppression, number of transplanted cells, timing of cell injections, and number of cell doses. Through a minimal dose of irradiation of 1Gy (100 Rads) or 2Gy, two injections of BM cells within the first 24h after myelosuppression resulted in engraftment in 100% of mice and a sustained therapeutic mixed chimerism in ?-thalassemia, while three to four injections were needed to achieve a similar outcome in SCD. Following the success of these trials, we modified this novel HSCT strategy and applied it to determine whether we can protect mice from lethal stroke induced through the Middle Cerebral Artery Occlusion (MCAO). Ischemia/reperfusion resulted in a major infarct that propagated over time to encompass ~70% of the affected hemisphere. When two doses of HSCs were injected at 2h and 24h after the reperfusion, 40% of mice survived, visible neurological defects disappeared, and the infarct size was reduced by two to four fold. Histological examination of brains in surviving mice revealed very few donor cells in the recipient brains, decreased total neurons count and increased glial cell numbers. These data suggest that the neuro-protection was not dependent on cell-supplementation, but rather the protection is manifested likely through growth factor secretion. Combined, these studies create a novel HSCT approach that has proved efficient for the treatment of various disorders. A \"window of opportunity\" exists for each disease where the donor cells should be administered, and multiple injections of donor HSCs can rescue diseases that would otherwise not be treatable. We ","PeriodicalId":53626,"journal":{"name":"Journal of Stem Cells","volume":"9 3","pages":"163-97"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32613357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chick embryogenesis: a unique platform to study the effects of environmental factors on embryo development. 鸡胚发生:研究环境因素对胚胎发育影响的独特平台。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2014-01-01 DOI: jsc.2014.9.1.17
S Yahav, J Brake

Bird embryogenesis takes place in a relatively protected environment that can be manipulated especially well in domestic fowl (chickens) where incubation has long been a commercial process. The embryonic developmental process has been shown to begin in the oviduct such that the embryo has attained either the blastodermal and/or gastrulation stage of development at oviposition. Bird embryos can be affected by "maternal effects," and by environmental conditions during the pre-incubation and incubation periods. "Maternal effects" has been described as an evolutionary mechanism that has provided the mother, by hormonal deposition into the yolk, with the potential to proactively influence the development of her progeny by exposing them to her particular hormonal pattern in such a manner as to influence their ability to cope with the expected wide range of environmental conditions that may occur post-hatching. Another important aspect of "maternal effects" is the effect of the maternal nutrient intake on progeny traits. From a commercial broiler chicken production perspective, it has been established that greater cumulative nutrient intake by the hen during her pullet rearing phase prior to photostimulation resulted in faster growing broiler progeny. Generally, maternal effects on progeny, which have both a genetic and an environmental component represented by yolk hormones deposition and embryo nutrient utilization, have an important effect on the development of a wide range of progeny traits. Furthermore, commercial embryo development during pre-incubation storage and incubation, as well as during incubation per se has been shown to largely depend upon temperature, while other environmental factors that include egg position during storage, and the amount of H2O and CO2 lost by the egg and the subsequent effect on albumen pH and height during storage have become important environmental factors to be considered for successful embryogenesis under commercial conditions. Manipulating environmental temperature during the period of egg storage, during the intermediate pre-incubation period, and incubation period per se has been found to significantly affect embryo development, hatching progress, chick quality at hatching, and chick development post-hatching. These temperature manipulations have also been shown to affect the acquisition of thermotolerance to subsequent post-hatching thermal challenge. This chapter will focus on: a. "maternal effects" on embryo and post-hatching development; b. environmental effects during the post-ovipositional period of egg storage, the intermediate pre-incubation period, and incubation period per se on chick embryogenesis and subsequent post-hatching growth and development; and c. effects of temperature manipulations during the pre-incubation and incubation periods on acquisition of thermotolerance and development of secondary sexual characteristics in broiler chickens.

鸟类胚胎发生在一个相对受保护的环境中,这种环境可以很好地控制,特别是家禽(鸡),其中孵化长期以来一直是一种商业过程。胚胎发育过程已被证明在输卵管中开始,因此胚胎在产卵时已达到胚层和/或原肠胚发育阶段。鸟类胚胎可能受到“母体效应”以及孵化前和孵化期的环境条件的影响。"母体效应"被描述为一种进化机制,这种机制通过激素沉积到卵黄中,使母体有可能主动影响其后代的发育,使其暴露在母体特定的激素模式下,从而影响其应对孵化后可能出现的各种预期环境条件的能力。“母体效应”的另一个重要方面是母体营养摄入对后代性状的影响。从商业肉鸡生产的角度来看,已经确定在光刺激之前母鸡在小鸡饲养阶段的累积营养摄入量增加导致肉鸡后代生长更快。一般来说,母体对后代的影响对后代性状的发育具有重要影响,包括遗传和环境两方面的影响,如卵黄激素沉积和胚胎营养物质利用。此外,商业胚胎在孵育前储存和孵育期间以及孵育期间的发育已被证明在很大程度上取决于温度,而其他环境因素,包括鸡蛋在储存期间的位置,鸡蛋损失的H2O和CO2量以及随后对储存期间蛋白pH和高度的影响,已成为商业条件下胚胎成功发生的重要环境因素。研究发现,在鸡蛋贮藏期、孵化前期中期和孵化期控制环境温度对胚胎发育、孵化进度、孵化时的雏鸡质量和孵化后的雏鸡发育有显著影响。这些温度操作也被证明会影响对后续孵化后热挑战的热耐受性的获得。本章将着重于:a。“母体效应”对胚胎和孵化后发育的影响;B.产卵后鸡蛋储存期、中期孵化前期和孵化期本身对小鸡胚胎发生和随后孵化后生长发育的环境影响;c.孵育前和孵育期温度调控对肉鸡耐热性获得和第二性征发育的影响。
{"title":"Chick embryogenesis: a unique platform to study the effects of environmental factors on embryo development.","authors":"S Yahav,&nbsp;J Brake","doi":"jsc.2014.9.1.17","DOIUrl":"https://doi.org/jsc.2014.9.1.17","url":null,"abstract":"<p><p>Bird embryogenesis takes place in a relatively protected environment that can be manipulated especially well in domestic fowl (chickens) where incubation has long been a commercial process. The embryonic developmental process has been shown to begin in the oviduct such that the embryo has attained either the blastodermal and/or gastrulation stage of development at oviposition. Bird embryos can be affected by \"maternal effects,\" and by environmental conditions during the pre-incubation and incubation periods. \"Maternal effects\" has been described as an evolutionary mechanism that has provided the mother, by hormonal deposition into the yolk, with the potential to proactively influence the development of her progeny by exposing them to her particular hormonal pattern in such a manner as to influence their ability to cope with the expected wide range of environmental conditions that may occur post-hatching. Another important aspect of \"maternal effects\" is the effect of the maternal nutrient intake on progeny traits. From a commercial broiler chicken production perspective, it has been established that greater cumulative nutrient intake by the hen during her pullet rearing phase prior to photostimulation resulted in faster growing broiler progeny. Generally, maternal effects on progeny, which have both a genetic and an environmental component represented by yolk hormones deposition and embryo nutrient utilization, have an important effect on the development of a wide range of progeny traits. Furthermore, commercial embryo development during pre-incubation storage and incubation, as well as during incubation per se has been shown to largely depend upon temperature, while other environmental factors that include egg position during storage, and the amount of H2O and CO2 lost by the egg and the subsequent effect on albumen pH and height during storage have become important environmental factors to be considered for successful embryogenesis under commercial conditions. Manipulating environmental temperature during the period of egg storage, during the intermediate pre-incubation period, and incubation period per se has been found to significantly affect embryo development, hatching progress, chick quality at hatching, and chick development post-hatching. These temperature manipulations have also been shown to affect the acquisition of thermotolerance to subsequent post-hatching thermal challenge. This chapter will focus on: a. \"maternal effects\" on embryo and post-hatching development; b. environmental effects during the post-ovipositional period of egg storage, the intermediate pre-incubation period, and incubation period per se on chick embryogenesis and subsequent post-hatching growth and development; and c. effects of temperature manipulations during the pre-incubation and incubation periods on acquisition of thermotolerance and development of secondary sexual characteristics in broiler chickens. </p>","PeriodicalId":53626,"journal":{"name":"Journal of Stem Cells","volume":"9 1","pages":"17-37"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32614559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization, isolation, expansion and clinical therapy of human corneal epithelial stem/progenitor cells. 人角膜上皮干细胞/祖细胞的鉴定、分离、扩增和临床治疗。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2014-01-01 DOI: jsc.2014.9.2.79
De-Quan Li, Zhichong Wang, Kyung-Chul Yoon, Fang Bian

Stem cells can be defined as cells that have the capacity to self-renew and the ability to generate differentiated progeny or multiple cell lineages. True stem cells can turn into any type of cells, while progenitor cells are more or less committed to becoming cell types of a particular tissue. Human corneal epithelial stem cells (CESCs) represent a great example and model of adult stem or progenitor cells. Human CESCs have been identified to locate in the basal epithelial layer of the limbus, and thus also referred as to limbal stem cells. We would like to use the both terms, stem and progenitor cells in this chapter based on previous use in the literature for more than two decades. Although the CESCs have been identified to reside at the limbus and many stem cell markers have been proposed, there is no consensus to date regarding the definitive markers for CESCs, and identification and isolation of these cells are still challenging. Based on evaluation of a variety of proposed markers, we have characterized that the CESCs located in the basal layer of human limbal epithelium are small primitive cells expressing three patterns of molecular markers, which represent a unique phenotype of putative corneal epithelial stem or progenitor cells. Based on adult stem cell criteria and the putative limbal stem cell phenotype, our group has attempted to enrich for human CESCs through novel approaches including cell-sizing, adhering to extracellular matrix collagen type IV, and cell sorting for side population or for expression of ABCG2 or connexin 43 cell surface markers. The 5 clonogenic populations isolated from limbal epithelium and its cultures by different methods show the properties that are characteristics of adult stem/progenitor cells: 1) relatively undifferentiated, 2) high proliferative potential, 3) self-renewal. Expansion and cultivation of corneal epithelial progenitor cells have been achieved using different methods, such as limbal tissue explant culture, and limbal epithelial cell suspension co-culture with mouse 3T3 fibroblast feed layer. To avoid the use of xeno-components, two cell lines of commercial human fibroblasts have been identified that support human corneal epithelial regeneration, and have potential use in replacing mouse 3T3 cells for corneal tissue bioengineering. The concept of CESCs has formed the basis for identifying a class of blinding diseases that display features of corneal epithelial stem cell deficiency or limbal stem cell deficiency (LSCD), where the limbal epithelium is damaged. LSCD is characterized by persistent or recurrent epithelial defects, ulceration, corneal vascularization, chronic inflammation, scarring, and conjunctivalization (conjunctival epithelial ingrowth). Only transplantation of CESCs can restore vision. Due to an increasing shortage of corneal donors, corneal tissue engineering is becoming an important discipline that holds great promise for corneal reconstruction. CESCs and optical substr

干细胞可以被定义为具有自我更新能力和产生分化后代或多个细胞系的能力的细胞。真正的干细胞可以转化为任何类型的细胞,而祖细胞或多或少地致力于成为特定组织的细胞类型。人角膜上皮干细胞(CESCs)是成体干细胞或祖细胞的一个很好的例子和模型。人类CESCs已被确定位于角膜缘的基底上皮层,因此也被称为角膜缘干细胞。基于二十多年来文献中的使用,我们在本章中将使用干细胞和祖细胞这两个术语。尽管已经确定CESCs位于边缘,并且提出了许多干细胞标记物,但迄今为止,对于CESCs的最终标记物尚未达成共识,并且这些细胞的鉴定和分离仍然具有挑战性。基于对各种标记的评估,我们发现位于人角膜缘上皮基底层的CESCs是表达三种分子标记模式的小原始细胞,它们代表了假定的角膜上皮干细胞或祖细胞的独特表型。基于成体干细胞标准和假定的角膜缘干细胞表型,我们的团队尝试通过新的方法来富集人类CESCs,包括细胞大小、粘附细胞外基质胶原IV型、侧群细胞分选或表达ABCG2或connexin 43细胞表面标记物。从角膜缘上皮及其培养物中分离得到的5个克隆源性群体表现出成体干细胞/祖细胞的特征:1)相对未分化;2)高增殖潜能;3)自我更新。角膜上皮祖细胞的扩增和培养采用了不同的方法,如角膜缘组织外植体培养、角膜缘上皮细胞悬液与小鼠3T3成纤维细胞饲料层共培养。为了避免异种成分的使用,已经鉴定出两种商业人类成纤维细胞系,它们支持人类角膜上皮再生,并有可能用于替代小鼠3T3细胞用于角膜组织生物工程。CESCs的概念已经形成了识别一类致盲疾病的基础,这些疾病表现为角膜上皮干细胞缺乏症或角膜缘干细胞缺乏症(LSCD)的特征,其中角膜缘上皮受损。LSCD的特征是持续或复发性上皮缺损、溃疡、角膜血管化、慢性炎症、瘢痕形成和结膜化(结膜上皮向内生长)。只有移植CESCs才能恢复视力。由于角膜供体的日益短缺,角膜组织工程正成为角膜重建的一门重要学科。CESCs和光学基质是再生医学中角膜组织生物工程中最重要的因素。我们的团队最近探索了自然供体角膜基质在角膜组织工程中的应用。结合含有干细胞的新鲜角膜缘上皮和供体角膜基质(天然光学基质的重要来源),我们开发了具有增殖潜力的天然样角膜等效结构。这种角膜结构为角膜重建提供了一种新的临床细胞治疗方法。
{"title":"Characterization, isolation, expansion and clinical therapy of human corneal epithelial stem/progenitor cells.","authors":"De-Quan Li,&nbsp;Zhichong Wang,&nbsp;Kyung-Chul Yoon,&nbsp;Fang Bian","doi":"jsc.2014.9.2.79","DOIUrl":"https://doi.org/jsc.2014.9.2.79","url":null,"abstract":"<p><p>Stem cells can be defined as cells that have the capacity to self-renew and the ability to generate differentiated progeny or multiple cell lineages. True stem cells can turn into any type of cells, while progenitor cells are more or less committed to becoming cell types of a particular tissue. Human corneal epithelial stem cells (CESCs) represent a great example and model of adult stem or progenitor cells. Human CESCs have been identified to locate in the basal epithelial layer of the limbus, and thus also referred as to limbal stem cells. We would like to use the both terms, stem and progenitor cells in this chapter based on previous use in the literature for more than two decades. Although the CESCs have been identified to reside at the limbus and many stem cell markers have been proposed, there is no consensus to date regarding the definitive markers for CESCs, and identification and isolation of these cells are still challenging. Based on evaluation of a variety of proposed markers, we have characterized that the CESCs located in the basal layer of human limbal epithelium are small primitive cells expressing three patterns of molecular markers, which represent a unique phenotype of putative corneal epithelial stem or progenitor cells. Based on adult stem cell criteria and the putative limbal stem cell phenotype, our group has attempted to enrich for human CESCs through novel approaches including cell-sizing, adhering to extracellular matrix collagen type IV, and cell sorting for side population or for expression of ABCG2 or connexin 43 cell surface markers. The 5 clonogenic populations isolated from limbal epithelium and its cultures by different methods show the properties that are characteristics of adult stem/progenitor cells: 1) relatively undifferentiated, 2) high proliferative potential, 3) self-renewal. Expansion and cultivation of corneal epithelial progenitor cells have been achieved using different methods, such as limbal tissue explant culture, and limbal epithelial cell suspension co-culture with mouse 3T3 fibroblast feed layer. To avoid the use of xeno-components, two cell lines of commercial human fibroblasts have been identified that support human corneal epithelial regeneration, and have potential use in replacing mouse 3T3 cells for corneal tissue bioengineering. The concept of CESCs has formed the basis for identifying a class of blinding diseases that display features of corneal epithelial stem cell deficiency or limbal stem cell deficiency (LSCD), where the limbal epithelium is damaged. LSCD is characterized by persistent or recurrent epithelial defects, ulceration, corneal vascularization, chronic inflammation, scarring, and conjunctivalization (conjunctival epithelial ingrowth). Only transplantation of CESCs can restore vision. Due to an increasing shortage of corneal donors, corneal tissue engineering is becoming an important discipline that holds great promise for corneal reconstruction. CESCs and optical substr","PeriodicalId":53626,"journal":{"name":"Journal of Stem Cells","volume":"9 2","pages":"79-91"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32615285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of MicroRNAs in Endothelial Progenitor Cells: Implication for Cardiac Repair. microrna在内皮祖细胞中的作用:对心脏修复的意义。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2014-01-01 DOI: jsc.2014.9.2.107
E Goretti, D R Wagner, Y Devaux

Endothelial progenitor cells (EPC) are mobilized after myocardial infarction (MI) from the bone marrow to injured sites of the heart where they participate in cardiac repair by revascularization of ischemic tissues. Endothelial progenitor cells have been actively studied, but their exact phenotype and regenerative properties are still controversial. Small trials with progenitor cells of different origins showed modest clinical benefits. It is assumed that a better understanding of the biology of EPC will contribute to improve their therapeutic potential. MicroRNAs (miRNAs) are small single-stranded non-coding RNAs that modulate gene expression by interacting post transcriptionally with protein-coding RNAs. MicroRNAs regulate multiple biological processes involved in cardiac development and disease. While many studies addressed the role of miRNAs in cardiac cells, less is known of the effect of miRNAs in EPC. Recent studies showed that miRNAs indeed regulate the biology of EPC. Since novel technologies to enhance or blunt the functions of miRNAs have been recently developed, it is conceivable that miRNAs may become promising new therapeutic tools. This article will review the recent advances in the knowledge of the effects of miRNAs in EPC and will discuss how miRNAs could be manipulated to improve the regenerative capacities of EPC in the diseased heart.

内皮祖细胞(EPC)在心肌梗死(MI)后从骨髓被动员到心脏损伤部位,在那里它们通过缺血组织的血运重建参与心脏修复。内皮祖细胞已被广泛研究,但其确切的表型和再生特性仍存在争议。不同来源祖细胞的小型试验显示出适度的临床益处。人们认为,更好地了解EPC的生物学将有助于提高其治疗潜力。MicroRNAs (miRNAs)是一种小的单链非编码rna,通过转录后与蛋白质编码rna相互作用来调节基因表达。MicroRNAs调节涉及心脏发育和疾病的多种生物过程。虽然许多研究解决了mirna在心脏细胞中的作用,但对mirna在EPC中的作用知之甚少。最近的研究表明,mirna确实调控了EPC的生物学。由于最近开发了增强或减弱mirna功能的新技术,可以想象mirna可能成为有希望的新治疗工具。本文将回顾mirna在EPC中作用的最新进展,并讨论如何操纵mirna来提高病变心脏EPC的再生能力。
{"title":"Role of MicroRNAs in Endothelial Progenitor Cells: Implication for Cardiac Repair.","authors":"E Goretti,&nbsp;D R Wagner,&nbsp;Y Devaux","doi":"jsc.2014.9.2.107","DOIUrl":"https://doi.org/jsc.2014.9.2.107","url":null,"abstract":"<p><p>Endothelial progenitor cells (EPC) are mobilized after myocardial infarction (MI) from the bone marrow to injured sites of the heart where they participate in cardiac repair by revascularization of ischemic tissues. Endothelial progenitor cells have been actively studied, but their exact phenotype and regenerative properties are still controversial. Small trials with progenitor cells of different origins showed modest clinical benefits. It is assumed that a better understanding of the biology of EPC will contribute to improve their therapeutic potential. MicroRNAs (miRNAs) are small single-stranded non-coding RNAs that modulate gene expression by interacting post transcriptionally with protein-coding RNAs. MicroRNAs regulate multiple biological processes involved in cardiac development and disease. While many studies addressed the role of miRNAs in cardiac cells, less is known of the effect of miRNAs in EPC. Recent studies showed that miRNAs indeed regulate the biology of EPC. Since novel technologies to enhance or blunt the functions of miRNAs have been recently developed, it is conceivable that miRNAs may become promising new therapeutic tools. This article will review the recent advances in the knowledge of the effects of miRNAs in EPC and will discuss how miRNAs could be manipulated to improve the regenerative capacities of EPC in the diseased heart. </p>","PeriodicalId":53626,"journal":{"name":"Journal of Stem Cells","volume":"9 2","pages":"107-15"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32615288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical safety in using unmatched allogeneic umbilical cord blood mononuclear cells transplantations in non-haematopoietic degenerative conditions. 非造血退行性疾病中使用不匹配的同种异体脐带血单个核细胞移植的临床安全性。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2014-01-01 DOI: jsc.2015.9.4.219
Rajni Vyas, Daya Dudhat, Pramodkumar Navik, Niyati Sudhalkar, Vaishali Garg, Jaymesh Thadani, Anant Marathe, Ramesh Bhonde, Bhaskar Vyas, Kaushik Deb

Aim: Evaluation of safety in using unmatched human allogeneic umbilical cord blood cells for therapeutic use in individuals with non-haematopoietic degenerative conditions.

Background: The historical data and several recent immunological arguments suggest the therapeutic use of allogeneic Cord Blood Mononuclear Cells (CBMNCs), as these cells do not elicit immune response. Customarily, HLA matched cord blood MNCs are used along with prolonged immunosuppression in treatment of haematological conditions. Lately, unmatched CBMNCs are widely used in case of unavailability of HLA matched cord blood. There have been suggestions for using unmatched allogeneic cord blood MNCs for degenerative conditions without an immunoconditioning regimen.

Method: 49 patients with non-haematopoietic degenerative conditions were treated with HLA-unmatched allogeneic hUCB MNCs. Intrathecal/I.V injections (1-2 million cells/kg body weight) were given. Clinical, biochemical and haematological adverse events were evaluated.

Results: The haematological and biochemical parameters showed no major deviation from the normal. Clinically, no acute adverse effects or GVHD were observed with the used dosage.

Conclusion: This study supports/suggests clinical safety in therapeutic medical use of unmatched allogeneic CBMNCs when used at low dosage in non-haematopoietic degenerative conditions.

目的:评价使用不匹配的人类异体脐带血细胞治疗非造血退行性疾病的安全性。背景:历史数据和最近的一些免疫学争论表明异体脐带血单核细胞(cbmnc)的治疗应用,因为这些细胞不会引起免疫反应。通常,HLA匹配的脐带血MNCs与长期免疫抑制一起用于血液病的治疗。近年来,不匹配脐带血被广泛应用于无法获得HLA匹配脐带血的情况。有建议使用不匹配的异体脐带血跨国公司退行性疾病没有免疫调节方案。方法:对49例非造血退行性疾病患者进行hla不匹配异体hub MNCs治疗。鞘内/我。注射V(1-2百万细胞/kg体重)。评估临床、生化和血液学不良事件。结果:血液学、生化指标与正常无明显偏差。临床使用剂量未见急性不良反应或GVHD。结论:本研究支持/建议在非造血退行性疾病中低剂量使用不匹配的同种异体cbmnc治疗性医学应用的临床安全性。
{"title":"Clinical safety in using unmatched allogeneic umbilical cord blood mononuclear cells transplantations in non-haematopoietic degenerative conditions.","authors":"Rajni Vyas,&nbsp;Daya Dudhat,&nbsp;Pramodkumar Navik,&nbsp;Niyati Sudhalkar,&nbsp;Vaishali Garg,&nbsp;Jaymesh Thadani,&nbsp;Anant Marathe,&nbsp;Ramesh Bhonde,&nbsp;Bhaskar Vyas,&nbsp;Kaushik Deb","doi":"jsc.2015.9.4.219","DOIUrl":"https://doi.org/jsc.2015.9.4.219","url":null,"abstract":"<p><strong>Aim: </strong>Evaluation of safety in using unmatched human allogeneic umbilical cord blood cells for therapeutic use in individuals with non-haematopoietic degenerative conditions.</p><p><strong>Background: </strong>The historical data and several recent immunological arguments suggest the therapeutic use of allogeneic Cord Blood Mononuclear Cells (CBMNCs), as these cells do not elicit immune response. Customarily, HLA matched cord blood MNCs are used along with prolonged immunosuppression in treatment of haematological conditions. Lately, unmatched CBMNCs are widely used in case of unavailability of HLA matched cord blood. There have been suggestions for using unmatched allogeneic cord blood MNCs for degenerative conditions without an immunoconditioning regimen.</p><p><strong>Method: </strong>49 patients with non-haematopoietic degenerative conditions were treated with HLA-unmatched allogeneic hUCB MNCs. Intrathecal/I.V injections (1-2 million cells/kg body weight) were given. Clinical, biochemical and haematological adverse events were evaluated.</p><p><strong>Results: </strong>The haematological and biochemical parameters showed no major deviation from the normal. Clinically, no acute adverse effects or GVHD were observed with the used dosage.</p><p><strong>Conclusion: </strong>This study supports/suggests clinical safety in therapeutic medical use of unmatched allogeneic CBMNCs when used at low dosage in non-haematopoietic degenerative conditions.</p>","PeriodicalId":53626,"journal":{"name":"Journal of Stem Cells","volume":"9 4","pages":"219-24"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33155602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative evaluation of efficacy of stem cells in combination with PLA/PGA membrane versus sub-epithelial connective tissue for the treatment of multiple gingival recession defects: a clinical study. 干细胞联合PLA/PGA膜与亚上皮结缔组织治疗多发性牙龈退缩缺损的临床研究
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2014-01-01 DOI: jsc.2015.9.4.253
Kushal Zanwar, Manohar Laxmanrao Bhongade, Kiran Kumar Ganji, Somnath B Koudale, Purushothama Gowda

Background: Umbilical Mesenchymal Stem Cells possess immunoregulatory capacities that have been permissive to allogenic transplantation. Recent animal studies have demonstrated histologically that bone marrow- derived mesenchymal stem cells (MSCs) may enhance the regeneration of periodontal defects in dogs by differentiating MSCs into cementoblasts, osteoblasts and periodontal fibroblasts.

Aim: To compare the clinical efficacy between stem cells in combination with PLA/PGA membrane and subepithelial connective tissue graft (SCTG) in the treatment of multiple gingival recession defects.

Methods: Twenty four patients aged between 20 to 33 years (mean age 27.41 ± 1.06 years) with multiple gingival recession defects on labial or buccal surface of the teeth in the aesthetic zone either in maxilla or mandible were treated. The test group was treated using stem cells cultured on bioresorbable PLA/PGA membrane, while control group was treated using SCTG. Following parameters were assessed, Plaque Index (PI),Gingival Bleeding Point Index (GBI), Relative gingival margin level (RGML), Relative attachment level (RAL) and Probing pocket depth (PPD) Results: In the test group, mean percent defect coverage was 72.43 ± 13.55 % and the predictability was 41.17% for root coverage i.e 14 of 34 defects, while in the control group, mean percent defect coverage was 82.06 ± 10.99 % and the predictability was 50 % for root coverage i.e 15 of 30 defects.

Conclusion: Stem cells in combination with bioresorbable PLA/PGA membrane was effective for root coverage resulted in a significant reduction in gingival recession, greater gain in CAL and WKG. Stem cells in combination with bioresorbable PLA/PGA membrane resulted in significantly higher CAL gain than SCTG.

背景:脐带间充质干细胞具有免疫调节能力,允许同种异体移植。最近的动物研究从组织学上证明,骨髓源性间充质干细胞(MSCs)可以通过分化成水泥母细胞、成骨细胞和牙周成纤维细胞来促进犬牙周缺损的再生。目的:比较干细胞联合聚乳酸/聚乳酸膜与上皮下结缔组织移植(SCTG)治疗多发性牙龈退缩缺损的临床疗效。方法:对24例年龄在20 ~ 33岁(平均27.41±1.06岁)的上颌、下颌骨美观区牙齿唇面或颊面多发龈退缩缺损患者进行治疗。试验组采用生物可吸收PLA/PGA膜培养的干细胞处理,对照组采用SCTG处理。参数评估后,菌斑指数(PI),牙龈出血指数(GBI),牙龈边缘的水平(RGML),附件的水平(、)和囊袋深度(产后抑郁症)结果:测试组,意味着缺陷百分比覆盖率为72.43±13.55%和可预测性是41.17%根报道即14 34的缺陷,而在对照组,意味着缺陷百分比覆盖率为82.06±10.99%和可预测性是50%根报道即15 30缺陷。结论:干细胞联合生物可吸收的PLA/PGA膜对牙根覆盖有效,可显著减少牙龈退缩,增加CAL和WKG。干细胞与生物可吸收的PLA/PGA膜结合后,CAL增益明显高于SCTG。
{"title":"Comparative evaluation of efficacy of stem cells in combination with PLA/PGA membrane versus sub-epithelial connective tissue for the treatment of multiple gingival recession defects: a clinical study.","authors":"Kushal Zanwar,&nbsp;Manohar Laxmanrao Bhongade,&nbsp;Kiran Kumar Ganji,&nbsp;Somnath B Koudale,&nbsp;Purushothama Gowda","doi":"jsc.2015.9.4.253","DOIUrl":"https://doi.org/jsc.2015.9.4.253","url":null,"abstract":"<p><strong>Background: </strong>Umbilical Mesenchymal Stem Cells possess immunoregulatory capacities that have been permissive to allogenic transplantation. Recent animal studies have demonstrated histologically that bone marrow- derived mesenchymal stem cells (MSCs) may enhance the regeneration of periodontal defects in dogs by differentiating MSCs into cementoblasts, osteoblasts and periodontal fibroblasts.</p><p><strong>Aim: </strong>To compare the clinical efficacy between stem cells in combination with PLA/PGA membrane and subepithelial connective tissue graft (SCTG) in the treatment of multiple gingival recession defects.</p><p><strong>Methods: </strong>Twenty four patients aged between 20 to 33 years (mean age 27.41 ± 1.06 years) with multiple gingival recession defects on labial or buccal surface of the teeth in the aesthetic zone either in maxilla or mandible were treated. The test group was treated using stem cells cultured on bioresorbable PLA/PGA membrane, while control group was treated using SCTG. Following parameters were assessed, Plaque Index (PI),Gingival Bleeding Point Index (GBI), Relative gingival margin level (RGML), Relative attachment level (RAL) and Probing pocket depth (PPD) Results: In the test group, mean percent defect coverage was 72.43 ± 13.55 % and the predictability was 41.17% for root coverage i.e 14 of 34 defects, while in the control group, mean percent defect coverage was 82.06 ± 10.99 % and the predictability was 50 % for root coverage i.e 15 of 30 defects.</p><p><strong>Conclusion: </strong>Stem cells in combination with bioresorbable PLA/PGA membrane was effective for root coverage resulted in a significant reduction in gingival recession, greater gain in CAL and WKG. Stem cells in combination with bioresorbable PLA/PGA membrane resulted in significantly higher CAL gain than SCTG.</p>","PeriodicalId":53626,"journal":{"name":"Journal of Stem Cells","volume":"9 4","pages":"253-67"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33274917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Stem Cells
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1